How Malaysia Proved Herbal Medicine Can Meet Western Clinical Standards Intriguing, narrative-driven.

Not All Herbs Are Good: The Honest Evidence from HMS 2026 That the World Needs to See Bold, truth-telling

Event: Herbal Medicine Symposium (HMS) 2026

Dates: April 7–8, 2026

Venue: National Institutes of Health (NIH), Setia Alam, Selangor, Malaysia

Organizer: Herbal Medicine Research Centre (HMRC), Institute for Medical Research (IMR)

Officiating Authority: YBhg. Datuk Seri Haji Hasnol Zam Zam bin Haji Ahmad, Secretary-General, Ministry of Health Malaysia

Theme: Advancing Science, Innovation and Future Global Market Access. 

YBhg. Datuk Seri Haji Hasnol Zam Zam bin Haji Ahmad

Secretary-General, Ministry of Health Malaysia.

  

The HMS 2026 was convened to address a critical intersection in global healthcare: the integration of traditional herbal medicine into evidence-based, clinically regulated practice. With the rise of herbal product usage worldwide, regulators & clinicians face the same core question - which herbs, supported by which evidence, are safe & effective for human treatment? 

Highlights

·       Global Scientific Validation: Keynote presentations included Professor Michael Heinrich (University College London), reinforcing the symposium's alignment with international pharmaceutical ethnopharmacology standards.

 

Dr. Ami Mazlin Bin Syed Mohamed 

Director, National Institutes of Health Malaysia, ( NIH )

·       Regulatory Presence: The Medical Device Authority (MDA) and the Ministry of Health Malaysia (KKM) participated actively, underscoring that regulatory oversight applies equally to herbal & conventional interventions.

 

 

·       Open Public Exhibition: NPRA-registered herbal products & research showcases were presented transparently to the public, signaling Malaysia's readiness for global market access.

 

Medical Device Authority, Ministry Of Health Malaysia

The Evidence Standard Established

A defining feature of HMS 2026 was the demonstration that high-quality herbal clinical research must be built on the same diagnostic foundation as Western medicine.

One exhibitor, Biotropics Malaysia Berhad, presented PHYSTA - supported by 26 clinical studies - with all pathology data derived from MDA-approved diagnostic devices. Biomarkers included:

·       Full blood count

·       Creatinine (kidney function)

·       Liver Function Test (LFT)

·       Cholesterol panel

·       Uric acid

·       HbA1c

·       Comprehensive – full blood test.

 

This framework ensures that herbal medicine data is regulator-compliant, reproducible & internationally readable- meeting the same evidentiary standards expected of pharmaceutical clinical trials.

 

Strategic Positioning: The MDA Connection

 

The exhibition layout placed Biotropics just four booths away from the MDA. This physical proximity symbolized a deeper principle: evidence accountability. Any product claiming clinical benefit must stand within measurable distance of the authority that certifies diagnostic accuracy. HMS 2026 made that relationship visible.

 

The Herbal Medicine Symposium 2026 did not claim universal readiness for all traditional products. Instead, it established a replicable model:

 

·       Regulatory alignment (MDA, NPRA, KKM)

·       Clinical rigor (pathology-based, MDA-approved devices)

·       International collaboration (global keynote speakers)

·       Public transparency (open exhibition)

 

For the international community, HMS 2026 demonstrated that traditional herbal medicine, when studied under Western clinical standards, can move from anecdote to evidence & from evidence to hospital formulary.

 

PRIORITY.

Western journal editors, regulatory bodies, and pharmaceutical stakeholders are encouraged to monitor Malaysian herbal clinical research post-HMS 2026, particularly products such as PHYSTA, which have already met the pathology-based, device-verified standard of evidence required for serious clinical consideration.

 

 

International regulatory and clinical audiences

Based on: HMS 2026 proceedings, NIH Malaysia, MDA regulatory framework & PHYSTA 26-study data.

 

The Green Light to the Hospital Pharmacy

The Herbal Medicine Symposium 2026 (NIH Malaysia)

 

The Crossroads of Tradition and Science

Imagine a bustling auditorium at the National Institutes of Health (NIH) in Setia Alam, Malaysia. The date is April 7th, 2026.

 

This is not just another academic event. This is the Herbal Medicine Symposium 2026, organized by the NIH. But for the herbal industry, this venue represents the gateway to the future. For years, herbal products have lived on shop shelves or in home remedies. The message of HMS 2026 is clear: The future is integration into clinical hospital practice .

 

https://www.linkedin.com/posts/institute-for-medical-research-malaysia_hms2026-biotechnology-herbalmedicine-activity-7420456689407221760-1dbJ

 

https://www.linkedin.com/posts/activity-7425056086006652928-1_a7

 

Beyond the Bottle.

The story of the herbal industry has always had a "happily ever after" in mind: to treat patients in hospitals. But to get that Hollywood ending, the industry needed two things:

 

1. Scientific Credibility: Published, clinically proven data.

2. Regulatory Approval: A nod from the Ministry of Health.

 

The Symposium, collaborating with the National Pharmaceutical Regulatory Agency (NPRA), is the plot twist that solves both. It is a strategic platform designed to align Malaysian herbs with international pharmaceutical standards .

 

The Protagonist: PHYSTA (The 26-Study Hero)

Every great story has a hero that paves the way. Enter PHYSTA.

Imagine PHYSTA not as a product, but as a golden case study. It arrives at the Symposium backed by 26 clinical studies. This isn't just herbal medicine; this is evidence-based medicine. PHYSTA acts as the protagonist showing the industry how it is done.

 

·       The Journey: With 26 studies, PHYSTA transforms from a "traditional claim" to a "clinically proven fact."

 

·       The Climax: Because of this data, PHYSTA gains the recognition necessary to cross the threshold from the herbal shop into the clinic & hospital to treat patients.

 

This is the "PHYSTA Effect"

The NIH isn't just hosting a talk fest; they are providing the toolkit. As an industry participant, you get access to:

 

1.      The Journal (IMRJ): The NIH hosts the Institute for Medical Research Journal (IMRJ) , which specifically lists "Herbal Medicine" as a key scope. This is your direct pathway to getting published & achieving that "clinically proven" status. https://imrj.nih.gov.my/about/aims-and-scope   

 

2.      The Regulators: NPRA is in the room. You get direct insight into what it takes to get approved.

 

3.      Global Experts: Keynote speakers like Prof. Michael Heinrich (UCL) and Prof. Dato’ Dr. Ibrahim Jantan are there to guide you on how to standardize your product for global markets .

 

A Prescription for the Industry

By attending this Symposium, you stop being just a manufacturer & become a stakeholder in national healthcare.

The Malaysian government has the framework (Act 775) and the hospital infrastructure ready for Traditional and Complementary Medicine (T&CM) .

http://hq.moh.gov.my/tcm/en/index.php/policy/guideline

 

https://bvsalud.org/portal-lis/en/lis-search/resource/?id=49970

 

https://www.pacificbridgemedical.com/news-brief/malaysia-s-ministry-of-health-introduces-the-traditional-and-complementary-medicine-act/

 

They are looking for products with the evidence to fill those hospital wards.

The Symposium promises to bridge the gap between the Exhibition Booth & the Hospital Pharmacy.

 

 

 

 

 

"Advancing Science, Innovation & Future Global Market Access"

NIH Setia Alam, April 7–8, 2026

·       Research: Get your products studied & published in the NIH journal .

 

·       Recognition: Use the symposium to network with regulators (NPRA) to understand approval pathways.

 

·       Result: Move your products from "traditional use" to "hospital formulary" status.

 

 

 

 Mmmmmmm

 

The Corridor of Evidence

How the Herbal Medicine Symposium 2026 Bridged Tradition & Western Clinical Standards

 

A Ceremony of Consequence

The National Institutes of Health (NIH) Malaysia stood host to a gathering that carried unusual weight.

The Herbal Medicine Symposium (HMS) 2026 was officially opened by YBhg. Datuk Seri Haji Hasnol Zam Zam bin Haji Ahmad, Secretary-General of the Ministry of Health Malaysia.

 

His presence sent a clear signal: this was not a trade fair.

This was a policy-level endorsement of evidence-based herbal medicine.

 

The theme was announced:

"Advancing Science, Innovation and Future Global Market Access"

 

Organized by the Herbal Medicine Research Centre (HMRC) of the Institute for…

How One Herbal Company Proved Itself at the NIH Symposium

The exhibition hall is a precise map of Malaysia's biomedical ecosystem.

Around 20 booths stand in careful arrangement. Among them:

 

·       Jabatan Pertanian (DOA) – Putrajaya.

https://www.doa.gov.my/

 

·       Forest Research Institute Malaysia (FRIM).

https://www.frim.gov.my/

 

·       Ministry of Health Malaysia (KKM) – Regulatory arm

https://www.npra.gov.my/index.php/my/

 

·       Medical Device Authority (MDA) – The gatekeepers of clinical safety

https://portal.mda.gov.my/index.php

 

·        

 

& then, Biotropics Malaysia Berhad.

 

(the story begins).

 

Act I: The Accidental Proximity

 

Look at the floorplan.

 

Biotropics Malaysia Berhad – Booth 12.

Medical Device Authority (MDA) – Booth 16.

Just four booths apart.

 

At first glance, this seems like a simple logistical arrangement.

But to those who understand the language of clinical evidence, this proximity is a silent, powerful statement.

 

Between these four booths lies a corridor of scientific accountability.

Every researcher, every doctor, every scientist walking from MDA to Biotropics must pass through a simple question:

 

“What proof do you carry?”

 

Act II: The MDA Standard – No Shortcuts

 

The Medical Device Authority (MDA) does not grant approval for decoration.

Every medical device - every analyzer, every diagnostic tool used to generate clinical data -must be MDA-approved.

 

Why does this matter for herbal medicine?

 

Because high-quality pathology data does not come from guesswork.

It comes from MDA-approved machines running standardized, validated tests.

 

When Biotropics presents clinical evidence, it is built on:

 

·       Full blood count

·       Comprehensive metabolic panel

·       Creatinine (kidney function)

·       Liver Function Test (LFT)

·       Cholesterol panel

·       Uric acid

·       HbA1c

·       & more

 

Every single result traced back to an MDA-permitted device.

That means: international standard. No compromise.

Act III: The Hard Question Every Scientist Asks

At the Symposium, the audience is not casual.

They are scientists, doctors, clinical researchers, regulators.

 

They have seen herbs fail.

They have seen traditional medicine brought to the bench & walk away with incomplete data, weak biomarkers, no safety profile.

 

The question they will ask Biotropics is brutal but fair:

 

“Is your herb safe? Is it effective? Or is this just tradition dressed as medicine?”

 

& worse - they will ask:

“What happens if this herb is actually harmful to the human body?”

Because not all herbs are good.

Not all herbs are safe for all patients.

& without high-level pathology evidence, no responsible doctor would ever prescribe one.

 

Act IV: The 26-Study Answer

This is where PHYSTA becomes the protagonist.

PHYSTA arrives at the Symposium not with claims – but with 26 clinical studies.

Each study built on the same MDA-approved pathology foundation.

 

·       Kidney safety → Creatinine within normal range

·       Liver safety → LFT unremarkable

·       Metabolic impact → Cholesterol, uric acid, HbA1c monitored

·       Systemic effect → Full blood count tracked

The data does not hide.

It shows exactly what PHYSTA does & what it does not do.

 

& here is the powerful conclusion that PHYSTA allows Biotropics to state, quietly but firmly:

Traditional herbal medicine, when studied at this level, is neither behind Western medicine nor blindly ahead of it.

It is equal - where it meets the same evidence standard.

 

Where PHYSTA shows benefit, it stands.

Where PHYSTA shows no harm, it proves safety.

The data is honest. That is the highest form of scientific respect.

 

Act V: The 4-Booth Opportunity

Now back to the floorplan.

MDA is four booths away.

That means:

Every regulator, every policy maker, every hospital procurement officer walking past MDA will pass Biotropics.

 

This is not a coincidence to ignore.

“You just saw the authority that approves diagnostic devices. Now see the herbal product validated by those devices.”

For the scientists walking the hall:

They see a traditional herb company voluntarily submitting itself to the same pathology standards as pharmaceutical research.

 

The Standard That Protects the Patient

The Symposium is not a competition between herbs & drugs.

It is a shared commitment to patient safety.

 

The MDA ensures the tools are accurate.

PHYSTA’s 26 studies ensure the evidence is truthful.

Biotropics ensures the herb is accountable.

& the NIH Symposium 2026 provides the stage where all three meet  - everyone to see.

Not all herbs are good. But the ones that pass the MDA-approved pathology standard?

Those deserve to be seen. Studied. And trusted.

 

Those deserve to be seen. Studied. And trusted. 

BIOTROPICS MALAYSIA BERHAD 

https://web.biotropicsmalaysia.com/zul

Nu-Prep  60s  https://s.shopee.com.my/1qYnsXZfWj

 

Nu-Prep  60s - Twin Pack https://s.shopee.com.my/3qJsGIfmIG

 

Nu-Prep ERX https://s.shopee.com.my/4Awiey3cuz

 

Nu-Prep Eksekutif B Plus  https://s.shopee.com.my/70Gu2Cs24u